MPL- OXYCODONE/NALOXONE oxycodone hydrochloride / naloxone hydrochloride 5/2.5 mg modified release tablet blister pack

Šalis: Australija

kalba: anglų

Šaltinis: Department of Health (Therapeutic Goods Administration)

Veiklioji medžiaga:

oxycodone hydrochloride, Quantity: 5 mg; naloxone hydrochloride dihydrate, Quantity: 2.73 mg (Equivalent: naloxone hydrochloride?, Qty 2.5 mg)

Prieinama:

Mundipharma Pty Ltd

Vaisto forma:

Tablet, modified release

Sudėtis:

Excipient Ingredients: ethylcellulose; macrogol 3350; brilliant blue FCF aluminium lake; stearyl alcohol; polyvinyl alcohol; titanium dioxide; magnesium stearate; lactose monohydrate; purified talc; hyprolose

Vartojimo būdas:

Oral

Vienetai pakuotėje:

20, 60, 28

Recepto tipas:

(S8) Controlled Drug

Terapinės indikacijos:

MPL-Oxycodone/Naloxone modified release tablets are indicated for the management of severe pain where:,- other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and,- the pain is opioid-responsive; and ,- requires daily, continuous, long term treatment.,MPL-Oxycodone/Naloxone modified release tablets are not indicated for use in chronic noncancer pain other than in exceptional circumstances.,MPL-Oxycodone/Naloxone modified release tablets are not indicated as an as-needed (PRN) analgesia.,The naloxone component in a fixed combination with oxycodone is indicated for the therapy and/or prophylaxis of opioid-induced constipation.,MPL-Oxycodone/Naloxone is indicated as second line symptomatic treatment of patients with severe to very severe idiopathic restless legs syndrome after failure of dopaminergic therapy.

Produkto santrauka:

Visual Identification: blue, oblong tablets marked "OXN" on one side and "5" on other; Container Type: Blister Pack; Container Material: PVC/Al; Container Life Time: 3 Years; Container Temperature: Store below 25 degrees Celsius

Autorizacija statusas:

Registered

Leidimo data:

2022-10-17